Marinus Pharmaceuticals Inc. priced its underwritten public offering of 12 million common shares at $3.75 apiece.
The company expects to raise gross proceeds of about $45 million from the offering, before deducting the underwriting discounts and commissions and other offering expenses.
Underwriters have a 30-day option to buy up to an additional 1.8 million common shares.
Marinus plans to use net proceeds to advance the preclinical and clinical development of ganaxolone, including clinical trial expenses and trials for postpartum depression and its rare pediatric refractory epilepsy program; for regulatory, research and development, pre-commercial, general and administrative and manufacturing expenses; and for working capital and general corporate purposes.
The offering is expected to close on or around Dec. 17, subject to customary closing conditions.
Jefferies LLC and Leerink Partners LLC are acting as joint book-running managers for the offering, with Cantor Fitzgerald & Co. as lead manager and Robert W. Baird & Co. Inc. as co-manager.
Radnor, Pa.-based Marinus Pharmaceuticals develops and sells medicines to treat epilepsy and neuropsychiatric disorders.